Zimberelimab is a monoclonal antibody that targets the PD-1 receptor on T cells, blocking its interaction with PD-L1 and PD-L2 ligands. This inhibition restores T cell activity, enhancing the immune system’s ability to detect and destroy cancer cells. It is primarily used in immunotherapy for various solid tumors. The antibody has shown efficacy in treating non-small cell lung cancer (NSCLC), particularly in patients with high PD-L1 expression. It is also being evaluated in combination therapies for other cancers, including head and neck squamous cell carcinoma, melanoma, and bladder cancer. By reactivating anti-tumor immune responses, zimberelimab helps improve progression-free and overall survival in selected patient populations. Its use is typically guided by biomarker testing, ensuring treatment is directed toward patients most likely to benefit. Ongoing clinical trials continue to explore its potential in earlier lines of therapy and in combination with chemotherapy, radiotherapy, or other immune checkpoint inhibitors.